Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR, Balan A, Niknafs N, Avrutin E, Zhu L, Sausen M, Bradbury PA, O'Donnell-Tormey J, Gaudreau PO, Ding K, Dancey J. Anagnostou V, et al. Among authors: juergens ra. Nat Med. 2023 Oct;29(10):2559-2569. doi: 10.1038/s41591-023-02598-9. Epub 2023 Oct 9. Nat Med. 2023. PMID: 37814061 Free PMC article. Clinical Trial.
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.
Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB. Wrangle J, et al. Among authors: juergens ra. Oncotarget. 2013 Nov;4(11):2067-79. doi: 10.18632/oncotarget.1542. Oncotarget. 2013. PMID: 24162015 Free PMC article.
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.
Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, Cohen V, Deschenes J, Ionescu DN, Juergens R, Kamel-Reid S, Laurie SA, Liu G, Morzycki W, Tsao MS, Xu Z, Hirsh V. Melosky B, et al. Curr Oncol. 2016 Jun;23(3):196-200. doi: 10.3747/co.23.3120. Epub 2016 Jun 9. Curr Oncol. 2016. PMID: 27330348 Free PMC article.
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S. Rizvi NA, et al. Among authors: juergens ra. J Clin Oncol. 2016 Sep 1;34(25):2969-79. doi: 10.1200/JCO.2016.66.9861. Epub 2016 Jun 27. J Clin Oncol. 2016. PMID: 27354481 Free PMC article. Clinical Trial.
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, Shen Y, Harbison CT, Hellmann MD. Gettinger S, et al. Among authors: juergens ra. J Clin Oncol. 2016 Sep 1;34(25):2980-7. doi: 10.1200/JCO.2016.66.9929. Epub 2016 Jun 27. J Clin Oncol. 2016. PMID: 27354485 Free PMC article. Clinical Trial.
81 results